Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787779 | 0.89 | NOTUM (0.43) | CYP3A4ACHEHPGDPOLBNOTUM | |
| SCHEMBL610098 | 0.87 | CYP3A4 (0.55) | CYP3A4ACHEHPGDPOLBGLO1 | |
| SCHEMBL22754120 | 0.85 | CYP3A4 (0.50) | CYP3A4ACHEHPGDPOLBGLO1 | |
| SCHEMBL22083904 | 0.83 | CYP3A4 (0.50) | CYP3A4HPGDPOLBTSHRKDM4E | |
| SCHEMBL2021435 | 0.81 | CYP3A4 (0.50) | CYP3A4ACHEHPGDPOLBTSHR | |
| SCHEMBL31057270 | 0.81 | GAA (0.45) | HPGDNOTUMTSHRKDM4EGLA | |
| SCHEMBL516651 | 0.81 | NOTUM (0.41) | CYP3A4ACHEHPGDPOLBNOTUM | |
| SCHEMBL29070096 | 0.81 | NOTUM (0.41) | CYP3A4ACHEHPGDPOLBNOTUM | |
| SCHEMBL20561796 | 0.80 | CYP3A4 (0.68) | CYP3A4ACHEHPGDPOLBGLO1 | |
| SCHEMBL20503232 | 0.80 | CYP3A4 (0.68) | CYP3A4ACHEHPGDPOLBGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | CACCIOLA JOSEPH | 2010-12-23 | — | — | US | claimed |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-4628483-A1 | DIHYDROPHTHALAZINE-CONTAINING COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4558480-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | CYP3A4 1112/4885ACHE 1071/4885HPGD 1135/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP3A4 4744/4885ACHE 4291/4885HPGD 4612/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | CYP3A4 1095/4885ACHE 1263/4885HPGD 567/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CYP3A4 4744/4885ACHE 4286/4885HPGD 4612/4885 |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, CLN6, S1PR1 | CYP3A4 4138/4885ACHE 401/4885HPGD 3220/4885 |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | CYP3A4 1532/4885ACHE 849/4885HPGD 1421/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CYP3A4 4744/4885ACHE 4291/4885HPGD 4612/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | CYP3A4 3718/4885ACHE 1563/4885HPGD 2414/4885 |
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | GRM1, GRM3, GRM2 | CYP3A4 878/4885ACHE 1090/4885HPGD 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.